Antimicrobials in COVID-19 : strategies for treating a COVID-19 pandemic
© 2022 Walter de Gruyter GmbH, Berlin/Boston..
The COVID-19 pandemic continues to pose a serious global challenge, with the world engulfed in fighting second, third and fourth waves of the disease, which is reaching scary proportions in terms of cases and mortality in countries like India. Despite the urgent need of proven management protocols, there is still confusion about the best practices for treating COVID-19 with different pharmaceutical interventions. Antimicrobials are empirically used in COVID-19 patients. During the initial phase of this pandemic, hydroxychloroquine, ivermectin, azithromycin and doxycycline were widely suggested for possible prophylaxis or treatment for COVID-19 in outpatient as well as hospitalized settings. Various national and international guidelines recommended its use. However, cumulative evidence from subsequent clinical trials has revealed no significant clinical benefits in any setting, with the risk of adverse effects being high particularly in combination with azithromycin. Yet, there is continued use of antimicrobials particularly in outpatient settings which should be avoided because there is no justifiable rationale for doing so. Antimicrobial resistance (AMR) was one of the top problems for global public health before the coronavirus 2019 (COVID-19) pandemic began. AMR, which is already a difficult problem, must now be handled in the context of a changing healthcare sector.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of basic and clinical physiology and pharmacology - 34(2023), 4 vom: 01. Juli, Seite 429-444 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shukla, Ajay Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
83905-01-5 |
|---|
| Anmerkungen: |
Date Completed 01.08.2023 Date Revised 01.08.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1515/jbcpp-2022-0061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340320362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340320362 | ||
| 003 | DE-627 | ||
| 005 | 20231226004902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/jbcpp-2022-0061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340320362 | ||
| 035 | |a (NLM)35503307 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shukla, Ajay Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobials in COVID-19 |b strategies for treating a COVID-19 pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2023 | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a The COVID-19 pandemic continues to pose a serious global challenge, with the world engulfed in fighting second, third and fourth waves of the disease, which is reaching scary proportions in terms of cases and mortality in countries like India. Despite the urgent need of proven management protocols, there is still confusion about the best practices for treating COVID-19 with different pharmaceutical interventions. Antimicrobials are empirically used in COVID-19 patients. During the initial phase of this pandemic, hydroxychloroquine, ivermectin, azithromycin and doxycycline were widely suggested for possible prophylaxis or treatment for COVID-19 in outpatient as well as hospitalized settings. Various national and international guidelines recommended its use. However, cumulative evidence from subsequent clinical trials has revealed no significant clinical benefits in any setting, with the risk of adverse effects being high particularly in combination with azithromycin. Yet, there is continued use of antimicrobials particularly in outpatient settings which should be avoided because there is no justifiable rationale for doing so. Antimicrobial resistance (AMR) was one of the top problems for global public health before the coronavirus 2019 (COVID-19) pandemic began. AMR, which is already a difficult problem, must now be handled in the context of a changing healthcare sector | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a challenges | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Misra, Saurav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of basic and clinical physiology and pharmacology |d 1997 |g 34(2023), 4 vom: 01. Juli, Seite 429-444 |w (DE-627)NLM012656321 |x 2191-0286 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:4 |g day:01 |g month:07 |g pages:429-444 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/jbcpp-2022-0061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 4 |b 01 |c 07 |h 429-444 | ||